Pulse Biosciences, Inc.
14
5
5
7
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 40/100
14.3%
2 terminated/withdrawn out of 14 trials
77.8%
-8.7% vs industry average
0%
0 trials in Phase 3/4
86%
6 of 7 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (14)
NS-PFA Catheter Ablation of Paroxysmal Atrial Fibrillation With the Pulse Biosciences CellFX System
Role: lead
CellFX® Nanosecond Pulsed Field Ablation (PFA) 360 Catheter Ablation System for Treatment of Atrial Fibrillation
Role: lead
Prospective Evaluation of the Pulse Biosciences nPulse™ Vybrance™ Percutaneous Electrode System
Role: lead
CellFX® nsPFA™ Cardiac Surgery System to Treat Atrial Fibrillation
Role: lead
CellFX® Nanosecond Pulsed Field Ablation (nsPFA)™ Cardiac Surgery Clamp System to Treat Atrial Fibrillation
Role: lead
CellFX ® Percutaneous Electrode (PE) Treatment of Symptomatic Benign Thyroid Nodules
Role: lead
Comparative Study Between CellFX and Electrodessication in Sebaceous Hyperplasia (SH) Lesions
Role: lead
Nano-Pulse Stimulation (NPS) in Sebaceous Hyperplasia
Role: lead
CellFX Comparison to Cryosurgery in Cutaneous Non-Genital Common Warts
Role: lead
Nano-Pulse Stimulation (NPS) in Seborrheic Keratosis Optimization Study
Role: lead
Nano-Pulse Stimulation (NPS) in Sebaceous Hyperplasia Optimization Study
Role: lead
Nano-Pulse Stimulation (NPS) in Seborrheic Keratosis Study
Role: lead
CellFX System for the Treatment of Cutaneous Non-Genital Warts
Role: lead
CellFX Treat & Resect Low-Risk BCC Feasibility Study
Role: lead
All 14 trials loaded